Immune globulin improved yield - ShireAlternative Names: BAX 1415; IG yield improvement
Latest Information Update: 15 Jun 2016
At a glance
- Originator Baxalta
- Developer Shire
- Class Immunoglobulins; Immunoproteins; Serum globulins
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Immunological disorders
Most Recent Events
- 03 Jun 2016 Baxalta has been acquired and merged into Shire